Atea Pharmaceuticals (NASDAQ:AVIR) Stock: Insider Bruce Polsky Sells 8,720 Shares

Atea Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director Bruce Polsky sold 8,720 Atea shares at an average $4.03, receiving about $35,142; he retained 158,580 shares. He also reported two other sales totaling 32,506 shares around the same period.
  • Atea shares rose 0.8% to $3.99 in Wednesday trading, below their 50-day and 200-day moving averages of $4.70 and $4.94, respectively.
  • The company reported a quarterly loss of $0.40 per share, better than analysts’ $0.51 loss estimate. Analysts’ average rating was Hold, with an $8 price target.
  • Interested in Atea Pharmaceuticals? Here are five stocks we like better.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) Director Bruce Polsky sold 8,720 shares of the business's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $4.03, for a total transaction of $35,141.60. Following the transaction, the director owned 158,580 shares of the company's stock, valued at $639,077.40. This trade represents a 5.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Bruce Polsky also recently made the following trade(s):

  • On Wednesday, November 18th, Bruce Polsky sold 18,252 shares of Atea Pharmaceuticals stock. The stock was sold at an average price of $3.95, for a total transaction of $72,095.40.
  • On Monday, November 16th, Bruce Polsky sold 14,254 shares of Atea Pharmaceuticals stock. The stock was sold at an average price of $4.27, for a total value of $60,864.58.

Atea Pharmaceuticals Stock Up 0.8%

Shares of AVIR stock traded up $0.03 on Wednesday, reaching $3.99. The company's stock had a trading volume of 342,250 shares, compared to its average volume of 307,434. The company has a market capitalization of $320.40 million, a P/E ratio of -2.05 and a beta of 0.76. Atea Pharmaceuticals, Inc. has a 12-month low of $2.92 and a 12-month high of $6.45. The stock's 50 day simple moving average is $4.70 and its 200-day simple moving average is $4.94.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.11. Research analysts expect that Atea Pharmaceuticals, Inc. will post -1.60 EPS for the current year.

Hedge Funds Weigh In On Atea Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Empowered Funds LLC purchased a new stake in shares of Atea Pharmaceuticals during the 3rd quarter valued at $475,000. Engineers Gate Manager LP bought a new stake in shares of Atea Pharmaceuticals during the 2nd quarter worth $78,000. Spark Investment Management LLC bought a new stake in shares of Atea Pharmaceuticals during the 2nd quarter worth $75,000. Headlands Technologies LLC bought a new stake in shares of Atea Pharmaceuticals during the 2nd quarter worth $77,000. Finally, Wellington Management Group LLP grew its position in Atea Pharmaceuticals by 262.7% in the second quarter. Wellington Management Group LLP now owns 206,785 shares of the company's stock worth $962,000 after acquiring an additional 149,776 shares in the last quarter. Institutional investors own 86.67% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on AVIR shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Atea Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen raised Atea Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, September 12th. Finally, Morgan Stanley boosted their price objective on Atea Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Atea Pharmaceuticals presently has an average rating of "Hold" and an average target price of $8.00.

Check Out Our Latest Stock Report on AVIR

About Atea Pharmaceuticals

(Get Free Report)

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company's investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Atea Pharmaceuticals Right Now?

Before you consider Atea Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.

While Atea Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines